Holen Sie sich die Stockscreener-App
14.58
7.60%
-1.20
Handel nachbörslich:
14.56
-0.02
-0.14%
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Teacher Retirement System of Texas Has $377,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $41.00 - Defense World
How the (IMVT) price action is used to our Advantage - news.stocktradersdaily.com
Immunovant stock hits 52-week low at $17.01 amid market challenges - Investing.com
Swiss National Bank Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News
Guggenheim Reiterates Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat
Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more - Endpoints News
Charles Schwab Investment Management Inc. Increases Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Immunovant price target raised to $61 from $58 at Stifel - Yahoo Finance
Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $17.15 amid market challenges - Investing.com Australia
Stifel raises Immunovant stock price target to $61 from $58 By Investing.com - Investing.com Canada
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate - TradingView
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright - Yahoo Finance
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - TradingView
Immunovant stock holds $51 target on positive trial data By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc. - Defense World
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - AOL
Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating - TipRanks
Immunovant will not seek approval for MG therapy, despite hitting endpoints - Yahoo Finance
Immunovant's muscle drug meets main goal, shares gain on new drug promise - Reuters.com
Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace
Immunovant stock hits 52-week low at $17.15 amid market challenges By Investing.com - Investing.com South Africa
Positive batoclimab data from Immunovant, but doubts raised on further development - The Pharma Letter
En garde, Vyvgart: Immunovant rolls out MG data - BioWorld MedTech
Immunovant's muscle drug data underwhelms, shares gain on new drug promise -March 19, 2025 at 08:12 am EDT - Marketscreener.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant stock Roivant stock slip on trial data (IMVT) - Seeking Alpha
Immunovant Says Currently Not Planning to Seek Approval of Batoclimab for Myasthenia Gravis; Shares Drop Pre-Bell - Marketscreener.com
Immunovant reports promising Phase 3 MG study results - Investing.com India
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 08:12 am EDT - Marketscreener.com
Immunovant stock falls despite study success By Investing.com - Investing.com South Africa
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - The Manila Times
Immunovant stock falls despite study success - Investing.com
Immunovant's muscle disorder treatment meets main goal in late-stage trial -March 19, 2025 at 07:52 am EDT - MarketScreener
Immunovant reports promising Phase 3 MG study results By Investing.com - Investing.com UK
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - The Manila Times
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP - Nasdaq
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from - Bakersfield.com
Critical Phase 3 Results: Immunovant's Breakthrough MG and CIDP Treatment Data Reveal Coming Next Week - StockTitan
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - AOL
Immunovant director Andrew Fromkin sells $156,768 in stock By Investing.com - Investing.com Australia
Immunovant director Andrew Fromkin sells $156,768 in stock - Investing.com India
Immunovant’s (IMVT) Buy Rating Reaffirmed at Guggenheim - Defense World
(IMVT) Investment Report - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus PT from Brokerages - The AM Reporter
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):